Pathway and network analysis of more than 2500 whole cancer genomes

0301 basic medicine /dk/atira/pure/subjectarea/asjc/1600/1600; name=General Chemistry Sustainable Development Goals Medizin General Physics and Astronomy Medical Genetics and Genomics PCAWG Drivers and Functional Interpretation Working Group Ecology,Evolution & Ethology Neoplasms name=General Biochemistry,Genetics and Molecular Biology Databases, Genetic Medicine and Health Sciences 2.1 Biological and endogenous factors 3100 Physics and Astronomy /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being; name=SDG 3 - Good Health and Well-being Precision Medicine Càncer Promoter Regions, Genetic SDG 3 Cancer Human Biology & Physiology /dk/atira/pure/subjectarea/asjc/1300/1300 Genome Q Biological Sciences 1600 Chemistry Medicinsk genetik och genomik /dk/atira/pure/subjectarea/asjc/3100/3100; name=General Physics and Astronomy 3. Good health TERT PROMOTER MUTATIONS Gene Expression Regulation, Neoplastic name=General Physics and Astronomy /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being Medical Genetics Genetics & Genomics /dk/atira/pure/subjectarea/asjc/1600/1600 Metabolic Networks and Pathways Biotechnology Human EXPRESSION 570 GENES 1300 Biochemistry 572 PROTEINS Science RNA Splicing Bioinformatics and Computational Biology Radboudumc 17: Women's cancers RIHS: Radboud Institute for Health Sciences 610 Genetics and Molecular Biology 610 Medicine & health Article Promoter Regions Databases 03 medical and health sciences Rare Diseases Cancer Genomics Genetic /dk/atira/pure/subjectarea/asjc/1300/1300; name=General Biochemistry,Genetics and Molecular Biology Genetics cancer Humans Medicinsk genetik Computational & Systems Biology Neoplastic Genome, Human Human Genome protein-coding Biology and Life Sciences PCAWG Consortium Computational Biology TLE4 General Chemistry SOMATIC MUTATIONS Tumour Biology mutations Chromatin Assembly and Disassembly ENCYCLOPEDIA Radboudumc 17: Women's cancers RIMLS: Radboud Institute for Molecular Life Sciences name=SDG 3 - Good Health and Well-being Genòmica Gene Expression Regulation Pan-Cancer Analysis of Whole Genomes (PCAWG) DISCOVERY General Biochemistry Mutation /dk/atira/pure/subjectarea/asjc/3100/3100 name=General Chemistry Genètica protein-coding genes, Mutation, genome sequencing, RNA splicing, cancer genomes Structural Biology & Biophysics
DOI: 10.1038/s41467-020-14367-0 Publication Date: 2020-02-05T19:03:29Z
AUTHORS (1455)
ABSTRACT
AbstractThe catalog of cancer driver mutations in protein-coding genes has greatly expanded in the past decade. However, non-coding cancer driver mutations are less well-characterized and only a handful of recurrent non-coding mutations, most notably TERT promoter mutations, have been reported. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2658 cancer across 38 tumor types, we perform multi-faceted pathway and network analyses of non-coding mutations across 2583 whole cancer genomes from 27 tumor types compiled by the ICGC/TCGA PCAWG project that was motivated by the success of pathway and network analyses in prioritizing rare mutations in protein-coding genes. While few non-coding genomic elements are recurrently mutated in this cohort, we identify 93 genes harboring non-coding mutations that cluster into several modules of interacting proteins. Among these are promoter mutations associated with reduced mRNA expression in TP53, TLE4, and TCF4. We find that biological processes had variable proportions of coding and non-coding mutations, with chromatin remodeling and proliferation pathways altered primarily by coding mutations, while developmental pathways, including Wnt and Notch, altered by both coding and non-coding mutations. RNA splicing is primarily altered by non-coding mutations in this cohort, and samples containing non-coding mutations in well-known RNA splicing factors exhibit similar gene expression signatures as samples with coding mutations in these genes. These analyses contribute a new repertoire of possible cancer genes and mechanisms that are altered by non-coding mutations and offer insights into additional cancer vulnerabilities that can be investigated for potential therapeutic treatments.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (52)
CITATIONS (85)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....